Implantable Devices to treat specific conditions
Shree Pacetronix Ltd., was founded in Pithampur, Dist. Dhar, India in 1988. In 1993 the company was converted to a Public Limited Company. The company is listed on the Bombay Stock Exchange and regional exchanges.
Pacetronix’s website shows EC type certificates for its Pinnacle SSIR (model 297), Pinnacle SSI (model 8820), Charak DDD (model ND 747), and Akash VDD (model ND 244) pacemakers. Continue reading
This is one of my most prized possessions. It is one of the very first pacemakers produced by CCC del Uruguay in 1969. It was given to me by my friend, the late Dr. Orestes Fiandra, founder of CCC del Uruguay.
On February 2, 1960, Dr. Orestes Fiandra and Dr. Roberto Rubio accomplished the first succesful long-term human implant of a pacemaker. The pacemaker was manufactured by Dr. Rune Elmqvist of Elema-Schönander in Sweden, and was implanted in Uruguay in a 34-year-old patient with AV block. This unit worked successfully for nine and a half months, until the patient died of sepsis from an unrelated infection.
In 1969, Dr. Fiandra started the “Centro de Construccion de Cardioestimuladores del Uruguay” (CCC for short) with the purpose of producing pacemakers for use in Latin America at prices well under those of American devices. The device in the photograph above is one of these devices – a simple VOO pacemaker powered by 5 mercury cells encapsulated in epoxy resin.
CCC is one of the oldest pacemaker manufacturers in the world. It was founded in 1969 by Dr. Orestes Fiandra, who performed the first succesful, human, long-term pacemaker implant in the world.This was achieved in Uruguay on February 2, 1960 by Dr. Orestes Fiandra and Dr. Roberto Rubio. The pacemaker was manufactured by Dr. Rune Elmqvist of Elema-Schönander in Sweden, and was implanted in Uruguay in a 34-year-old patient with AV block. This unit worked successfully for nine and a half months, until the patient died of sepsis from an unrelated infection. Continue reading
Omikron Scientific was a small-scale pacemaker company founded in Rehovot, Israel in 1979. The company stopped pacemaker production in 1985.
Besides pacemakers, Omikron also produced a skin substitute called Omniderm, which was a thin, transparent, flexible membrane. It was used when a biological dressing would otherwise have been used.
Omikron’s pacemakers were all VVI and featured gradual decline Magnet Rate & Programmed Rate. Models included the 811 (6.5 year longevity), 811L (10 year longevity), 811XL (14 year longevity), 821 (VVIM with 8 year longevity), 837, a 838 (6.5 year longevity).
Click here for Omikron’s patents.
From US Patent Application Publication US 2009/0163889 A1
MicroTransponder was founded in Dallas, TX in 2007 when it licensed technology developed at University of Texas in Dallas (UTD) by Larry Cauller, who heads the cortical connections lab. The first wireless transponder was developed under a DARPA Revolutionizing Prosthetics grant to create a bi-directional neural interface for a prosthetic hand. Continue reading
Northstar was founded in 1999 as Vertis Neuroscience headquartered in Seattle, WA, and the original goal was to develop electrical stimulation for chronic back pain. In 2003, under its new name, Northstar Neuroscience, then developed the Renova cortical stimulation system to deliver targeted electrical stimulation to the brain cortex as a treatment for stroke-related upper extremity. Continue reading
Intrapace was founded in Mountain View, CA by Mir Imran in 2001 to develop an implantable system for the treatment of obesity. Once implanted and activated, the Abiliti system is designed to detect when a person consumes food or drink. When food or drink is detected, the system delivers a series of low-energy electrical impulses to the stomach intended to create a feeling of fullness.
In January 2011 Intrapace received the CE Mark for the Ability system.
The Ability IPG connects to the stomach via a lead that integrates the food sensor and stimulation electrodes. The sensor is able to detect food and drink and can trigger the abiliti stimulator device to create a feeling of fullness. These eating events, along with physical activity the patient engages in, are automatically recorded and available for downloading to a personal computer using the connect.abiliti Wand. Continue reading
Transneuronix, Inc. was founded in 1995 and was based in Mount Arlington, New Jersey. It was acquired by Medtronic in 2005.
Before its acqusition by Medtronic, Transneuronix developed the Transcend, an implantable gastric stimulator device for the treatment of obesity by electrical stimulation of the stomach. Later, Medtronic developed the Transcend II IPG. Continue reading
EnteroMedics Inc. was founded in St. Paul, MN in 2002 to develop a platform for vagus-nerve stimulation, primarily for obesity management. In March 2011 EnteroMedics received the CE Mark for its second-generation system – the Maestro RC.
The EnteroMedics Maestro RC device delivers VBLOC® vagal blocking therapy to through laparoscopically implanted leads to intermittently block the vagus nerves using high-frequency, low-energy electrical impulses. VBLOC Therapy is intended to target the multiple digestive functions under control of the vagus nerves and to affect the perception of hunger and fullness. Continue reading
Image Credit: Biocontrol
In June 2011, Israeli neuromodulation systems developer BioControl Medical spun-off CerebralRx to market its FitNeS vagus nerve stimulation system for the treatment of refractory epilepsy.
The FitNes system employs platform technology developed for the CardioFit® system for treating congestive heart failure (HF). CerebralRx spun out of BioControl Medical to expand the use of this technology outside of cardiology for the treatment of a range of neurological disorders, including epilepsy.
From Patent Application Publication: US 2011/0137370 A1
Enopace Biomedical Ltd. was founded in 2008 by Yossi Gross in Caesarea, Israel.
Very scant details are available besides that it is developing a neuromodulation system to treat patients with congestive heart failure. According to the company, its technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload.
From Enopace’s patent applications, it seems that Enopace’s device consists of a stimulation unit that is placed within the aorta close to the heart, and which is driven wirelessly from a coil that is placed within a vein closeby to the artery. The transmitting coil is in turn driven from an implanted control unit that is implanted subcutaneously. Continue reading
Image Credit: CVRx
CVRx was founded in Minneapolis, MN in 2001 by Dr. Robert Kieval to develop an implantable system for the treatment of hypertension.
CVRx’s implantable pulse generators deliver stimulation to the baroeceptors in the carotid arteries to induce a baroreflex that causes a drop in blood pressure in patients with refractory hypertension. Continue reading
Second Sight Medical Products, Inc., located in Los Angeles, CA, was founded in 1998 by Alfred Mann to develop a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa.
Second Sight’s Argus II Retinal Prosthesis System is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals. The implant is an epiretinal prosthesis surgically implanted in and on the eye that includes an antenna, an electronics case, and an electrode array. The external equipment includes glasses, a video processing unit (VPU) and a cable.
© 2011 David Prutchi
St. Louis, MO startup EndoStim is developing an implantable stimulator to treat gastro-esophageal reflux disease (GERD) by delivering stimulation to the lower esophageal sphincter. The IPG is connected to an EndoStim implantable bipolar lead with electrodes that are stitched and secured into the lower esophageal sphincter muscle during laparoscopy. Continue reading
Sicel Technologies, Inc. was founded in 1999 and was based in Morrisville, NC. It ceased operations in 2010 after it declared bankruptcy.
Sicel developed an implantable dosimeter that was 2 mm in diameter and 18 mm long, and was injected into the tumor to send back readings to an external receiver via RFID. Continue reading